Arun Azad

Our latest manuscript in @eBioMedicine looking at DNA damage response (DDR) alterations in #ctDNA from a large cohort of mCRPC #prostatecancer pts. Weblink: rb.gy/zy3e8 Thanks to pts, families, investigators, @predicine, @KohliMask1020, Dr Heidi Fettke (1/9)

Amazing to see 2 simultaneous practice-changing pubs in @TheLancet showing efficacy of Enza+Tala in mCRPC - all comers, HRR+ and BRCA+. Proud to have been involved @PeterMacCC @gu_onc . Great leadership from #KarimFizazi & @neerajaiims

Consistent & practice-changing! Talazoparib + Enzalutamide improves OS in HRR-deficient mCRPC. OS: 45.1 vs 31.1 months (HR 0.62). BRCA1/2+: 4-year OS 53% vs 23%. A new SoC is here. @asco @oncoalert #prostatecancer #oncology @neerajaiims @CParkMD @TheLancet @APCCC_Lugano @Larvol…

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial buff.ly/A2GlREZ The final analysis of the TALAPRO-2 trial showed…

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few…

🥳 Today, we randomised the final patient on @TROGfightcancer 19.06 DECREASE trial! This trial randomised patients with prostate cancer who were becoming resistant to hormone therapy, without evidence of metastases on bone or CT scan, to Darolutamide +/- Stereotactic…

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial thelancet.com/journals/lanon… In the phase 3 CONTACT-02 trial, researchers evaluated the efficacy and safety of combining cabozantinib, a tyrosine…

Breaking news @ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall @AttardLab @PCF_Science @urotoday @OncoAlert

Mevrometostat in combination with enzalutamide in patients with #mCRPC previously treated with abiraterone acetate: The phase 3, randomized #MEVPRO-1 study. Presentation by @neerajaiims @huntsmancancer. #ASCO25 written coverage by @chavarriagaj @UofT > bit.ly/3SyaeZi…

Adds to the strong body of evidence also provided by #ENZAMET with 8yr OS data presented at #ASCO25 showing similar benefits. Enzalutamide is a highly active and very valuable treatment for #mHSPC #ProstateCancer. Great to see #ARCHES also continuing long follow-up.

🗣️Prostate Oral Abstract #ASCO25 👉Abst5005: Dr @AarmstrongDuke presenting 5⃣ yr follow up of pts w/ mCSPC on ENZA + ADT on #ARCHES n = 1150 💊ENZA + ADT 💊 PBO + ADT - 31% crossover to ENZA + ADT - median follow up: 61.4mo ENZA vs PBO…

Updated results from #ARCHES in mHSPC showing sustained benefits of #enzalutamide with minimum 5 year followup. 3 year survival benefit in high volume disease! Amazing results! @AarmstrongDuke @AzadOncology #ASCO25

Congrats @AarmstrongDuke for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC #prostatecancer with enzalutamide @ASCO #ASCO25 👉66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide👇@OncoAlert @urotoday @PCF_Science @AzadOncology

🔎Results of Terbium-161 PSMA radioligand therapy (attaches PSMA, Beta emitter w/ Auger electrons) in mCRPC: VIOLET trial ✅Low rate of toxicity (up to 7.4 GBq) w/ 7% G3-4 AE ✅PSA >/ 90% RR 40%, rPFS median 11.1m @ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday…

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3…

Just in @ASCO #ASCO25 👉oral presentation 👉Efficacy of enzalutamide+talazoparib vs enza in the ph3 TALAPRO-2 trial extends beyond BRCAm subgroup in mCRPC #prostatecancer 👇Congrats DrZschaebitz @OncoAlert @urotoday Median OS significantly improved in patient cohort with HRRm

Just in from @ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini @drmnstein and team @JCO_ASCO @OncoAlert @urotoday @PCF_Science

Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair…

Don't miss the first-in-human VIOLET study being presented #ASCO25 @ASCO Monday June 2 3:00 PM New Frontiers in Prostate-Specific Membrane Antigen Radioligand Therapy (awesome research being presented in this session - don't miss the other talks) In press @TheLancetOncol…

So great to work with you and the @ResearchWyatt team. You are number 1️⃣ globally 🥇